Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
Recombinant phenotyping of cytomegalovirus (CMV) pol region III mutations from clinical specimens showed that T813S and G841A each conferred foscarnet resistance and approximately threefold increased ganciclovir resistance; adding the UL97 mutation C592G increased ganciclovir resistance to approximately sixfold. Bacterial artificial chromosome CMV clones containing pol mutation L845P were nonviable unless repaired with the wild-type sequence.
Chou
Sunwen
S
Divisionof Infectious Disease, Oregon Health Science University, VA Medical Center, Portland, OR 97239, USA. chous@ohsu.edu
Marousek
Gail I
GI
Van Wechel
Laura C
LC
Li
Shaobing
S
Weinberg
Adriana
A
D000998:Antiviral Agents / Q000494:pharmacology*; D003587:Cytomegalovirus / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D003586:Cytomegalovirus Infections / Q000821:virology; D004259:DNA-Directed DNA Polymerase / Q000235:genetics*; D024882:Drug Resistance, Viral / Q000235:genetics*; D017245:Foscarnet / Q000494:pharmacology; D015774:Ganciclovir / Q000494:pharmacology; D005838:Genotype; D006801:Humans; D009154:Mutation; D010641:Phenotype
D000998:Antiviral Agents; D017245:Foscarnet; D004259:DNA-Directed DNA Polymerase; D015774:Ganciclovir
J Infect Dis. 1997 May;175(5):1087-92
9129070
J Infect Dis. 1997 Sep;176(3):786-9
9291334
J Virol. 1998 Jul;72(7):5927-36
9621055
J Infect Dis. 1998 Aug;178(2):526-30
9697736
Virology. 1998 Sep 1;248(2):382-93
9721246
J Virol. 1999 Oct;73(10):8320-9
10482582
Nature. 1992 Jul 9;358(6382):162-4
1319560
Antimicrob Agents Chemother. 2005 Mar;49(3):873-83
15728878
Nucleic Acids Res. 2005;33(4):e36
15731329
Antimicrob Agents Chemother. 2005 Jul;49(7):2710-5
15980340
J Biol Chem. 2006 Jun 30;281(26):18193-200
16638752
Antimicrob Agents Chemother. 2007 Jan;51(1):89-94
17043128
J Infect Dis. 2007 Jul 1;196(1):91-4
17538888
J Clin Microbiol. 2005 Jan;43(1):208-13
15634973